The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC).
Takuji Okusaka
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Masafumi Ikeda
Stock Ownership - Bayer; Chugai Pharma; Novartis
Honoraria - Bayer; Chugai Pharma; Novartis
Research Funding - Bayer; Chugai Pharma; Novartis
Shinichi Ohkawa
Stock Ownership - Chugai Pharma; Lilly; Taiho Pharmaceutical
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; OncoTherapy Science; Taiho Pharmaceutical; Takeda
Shunsuke Yamamoto
No relevant relationships to disclose
Ikue Suzuki
No relevant relationships to disclose
Junji Furuse
Honoraria - Bayer; Chugai Pharma; Eisai; Lilly; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; GlaxoSmithKline; Lilly; Taiho Pharmaceutical; Takeda
Expert Testimony - Bayer; Chugai Pharma; Eisai; GlaxoSmithKline; Lilly; Taiho Pharmaceutical